Efficacy and Safety of the Met+SGLT-2i+GLP-1RA in Patients With Type 2 Diabetes With Poor Glycemic Control
NCT07244003 on ClinicalTrials.gov · last registry update 2025-11-24
An unusually large phase 4: 430 participants, more than double the 72 typical for the stage. Due to report 31 December 2027, alongside 38 other tracked readouts that quarter. Primary outcome, as filed: The change of HbA1c compared to the baseline. Sponsors move these dates routinely; any movement since this site started watching is listed below. liraglutide is already approved in the US for type 2 diabetes, so this is asking a further question rather than establishing the drug works at all.
- Status
- RECRUITING
- Phase
- P4
- Drug
- liraglutideVictoza, Xultophy, Saxenda
- Sponsor
- Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
- Sponsor type
- Industry
- Enrollment
- 430
- Started
- 2025-03-29
- Primary completion
- 2027-12-31 estimated
Observed history
No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.
Primary outcome
The change of HbA1c compared to the baseline
Conditions studied
T2DM (Type 2 Diabetes Mellitus)
Every field above is taken directly from the registry record. See all detected changes across the class, or the liraglutide page for this molecule’s full trial and approval history.